- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01417065
Temsirolimus In Phase 0
Phase 0 Trial Evaluating the Effect of Temsirolimus on Known Pharmacodynamic Targets
The goal of this clinical research trial is to study the effects of the FDA-approved drug, temsirolimus, using a new type of clinical study design called a "Phase 0." This type of study may be able to predict if a drug can affect cancer and may be able to prevent potentially useful study drugs from being discarded before they are fully tested.
The purpose of the study is not to treat the cancer, but to help improve general cancer treatment knowledge.
Descripción general del estudio
Descripción detallada
Study Drug:
Temsirolimus is designed to block the growth of cancer cells, which may cause the cancer cells to die.
Study Drug Administration:
If you are found to be eligible to take part in this study, you will receive temsirolimus by vein over about 60 minutes on Day 1.
You will be assigned to a dose level of temsirolimus based on when you join this study. Up to 5 dose levels of temsirolimus will be tested. Up to 3 participants will be enrolled at each dose level. The first group of participants will receive the lowest dose level. Each new group will receive a higher dose than the group before it, until the drug is found to affect the enzyme that was tested for at screening.
Study Visits:
At each study visit, you will be asked about any drugs you may be taking and about any side effects you may be having.
On Day 1:
-Blood (about 2 teaspoons each time) will be drawn before you receive the study drug and 5 times over the 24 hours after you receive the study drug for pharmacokinetic (PK) testing. PK testing measures the amount of study drug in the body at different time points.
Blood (about 4 teaspoons each time) will be drawn for pharmacodynamic (PD) testing. PD testing measures how the level of study drug in your body may affect the disease. This blood will be drawn at 1 or more of the following times, but if the doctor thinks it is needed, blood will be drawn at 2 or all 3 of the following times:
- At 4 hours (+/- 2 hours) after the dose
- At 24 hours (+/- 3 hours) after the dose
- At 72 hours (+/- 24 hours) after the dose
After the blood for PD testing has been tested and the tests show that the study drug may be causing changes to the tumor cells in at least 2 out of 3 participants, future participants will have tumor tissue collected before and after dosing for testing. Leftover tissue from an earlier biopsy can be used instead of a fresh biopsy before dosing, if it is available.
Length of Study:
You will be on study for up to 4 days. You will be taken off study early if you have intolerable side effects.
Because it takes 4 days for temsirolimus to be completely processed by the body, you will not be able to begin receiving drugs in any other study until 4 days after the dose.
This is an investigational study. Temsirolimus is FDA approved and commercially available for the treatment of advanced renal cancer. Its use in other types of cancer is investigational.
Up to 30 patients will take part in this study. All will be enrolled at MD Anderson.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase temprana 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- UT MD Anderson Cancer Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Patients with advanced or metastatic cancer, preferably with tumor easily accessible for biopsy.
- Patients should be at least four weeks or 5 half lives from the last day of chemotherapy, antibody or other biological therapy, whichever is shorter.
- Patients should preferably be undergoing screening for 2007-0668, 2008-0384, 2008-0425, and 2008-0827 (currently active Phase I trials involving temsirolimus). However, patients may also be allowed on protocol if they are undergoing screening for any study.
Exclusion Criteria:
- Pregnant or lactating women.
- Patients with a known hypersensitivity to any of the components or metabolites of the drug products.
- Patients with a known bleeding diathesis which would prevent safely obtaining a biopsy if a biopsy is indicated.
- Patients who are less than 18 years of age.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Temsirolimus
Starting dose 0.02 mg intravenous administered once.
|
Starting dose will be 0.02 mg intravenous administered once on Day 1 over 60 minutes.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Participants' Pharmacodynamic (PD) Responses
Periodo de tiempo: Blood drawn at 4 hours (+/- 2 hours) after study drug
|
PD response, significant S6 Kinase 1 (S6K1) inhibition, is defined at both the patient level and the dose level, 1) as compared with baseline, at least 50% reductions of S6K1 after treatment (biological criterion); 2) differences in log transformed S6K1 activity between post-treatment and baseline should be greater than threshold of 1.8 times standard deviation (SD) of baseline, which yields a 90% statistical confidence that it is not due to chance variation (statistical criterion).
|
Blood drawn at 4 hours (+/- 2 hours) after study drug
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Daniel Karp, MD, UT MD Anderson Cancer Center
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 2010-0259
- NCI-2011-02799 (Identificador de registro: NCI CTRP)
- 2K12CA088084-12 (Subvención/contrato del NIH de EE. UU.)
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Cáncer avanzado
-
Advanced BionicsTerminadoPérdida auditiva severa a profunda | en usuarios adultos de Advanced Bionics HiResolution™ Bionic Ear SystemEstados Unidos
-
Abramson Cancer Center of the University of PennsylvaniaTerminadoPaciente con cancerEstados Unidos
-
Peking Union Medical College HospitalTerminadoEncuesta | Estado nutricional | Paciente con cancerPorcelana
-
Ankara Medipol UniversityReclutamientoCuidados personales | Inmunoterapia | Manejo de síntomas | Paciente con cancerPavo
-
Northwestern UniversityGenzyme, a Sanofi CompanyRetiradoCANCER DE PROSTATAEstados Unidos
-
Fundacao ChampalimaudTerminado
-
University College London HospitalsTerminado
-
GenSpera, Inc.RetiradoCancer de prostata.Estados Unidos
-
University of Colorado, DenverColorado State UniversityRetiradoRealidad virtual | Diagnóstico por imagen | Educación del paciente | Paciente con cancerEstados Unidos
-
Dana-Farber Cancer InstituteTerminadoCancer de RIÑON | Cancer de prostata | Cáncer genitourinarioEstados Unidos
Ensayos clínicos sobre Temsirolimus
-
Sheba Medical CenterStanley Medical Research InstituteDesconocidoEsquizofrenia | Trastorno esquizoafectivoIsrael
-
St. Joseph's Healthcare HamiltonPfizer; McMaster UniversityTerminadoCarcinoma de células renalesCanadá
-
AVEO Pharmaceuticals, Inc.Terminado
-
New Mexico Cancer Care AllianceWyeth is now a wholly owned subsidiary of PfizerTerminadoSarcomaEstados Unidos
-
Dana-Farber Cancer InstituteWyeth is now a wholly owned subsidiary of Pfizer; Millennium Pharmaceuticals,...TerminadoMieloma múltipleEstados Unidos
-
Children's Hospital Medical Center, CincinnatiRetiradoLinfoma de células B | Leucemia de células BEstados Unidos
-
Mathias Witzens-HarigCharite University, Berlin, Germany; Ludwig-Maximilians - University of Munich; Johann Wolfgang Goethe University Hospital y otros colaboradoresDesconocidoLinfoma difuso de células B grandesAlemania
-
Goethe UniversityTerminadoLeucemia mieloblástica agudaAlemania
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)Terminado
-
AGO Study GroupTerminadoEnfermedades Ováricas | Neoplasias Ováricas | Neoplasias Endometriales | Enfermedades Genitales FemeninasAlemania